BioCryst Pharma (BCRX) Peramivir NDA Acceptance an Important Achievement, Needham & Company Says
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $14 price target on BioCryst Pharma (NASDAQ: BCRX) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
